Clinical Trials Logo

CML, Relapsed clinical trials

View clinical trials related to CML, Relapsed.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03573596 Recruiting - CML, Relapsed Clinical Trials

Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

DASTOP2
Start date: February 1, 2018
Phase: Phase 2
Study type: Interventional

This study will enroll CML patients who have failed a first TKI stopping attempt. After failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment for another 2 years. If MR4 or better is re-achieved and maintained for at least one year, patients will be eligible for a second stop. After verification of MR4, TKI treatment will be stopped and patients followed in the same manner as after first stop. If MMR is lost (BCR-ABL >0.1% (IS)), TKI treatment will once again be restarted.